Literature DB >> 29051180

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.

Andrew H Wei1,2, Ing S Tiong1,2.   

Abstract

In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.
© 2017 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29051180     DOI： 10.1182/blood-2017-08-784066

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


  39 in total

Review 1.  Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.

Authors:  Sunil Adige; Rena G Lapidus; Brandon A Carter-Cooper; Alison Duffy; Ciera Patzke; Jennie Y Law; Maria R Baer; Nicholas P Ambulos; Ying Zou; Søren M Bentzen; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2019-04-09       Impact factor: 3.333

2.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

3.  Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.

Authors:  Tiffany M Scharadin; Michael A Malfatti; Kurt Haack; Kenneth W Turteltaub; Chong-Xian Pan; Paul T Henderson; Brian A Jonas
Journal:  Chem Res Toxicol       Date:  2018-09-10       Impact factor: 3.739

Review 4.  ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Authors:  Jianbiao Zhou; Yvonne Ng; Wee-Joo Chng
Journal:  Cell Mol Life Sci       Date:  2018-07-31       Impact factor: 9.261

5.  Can we forecast induction failure in acute myeloid leukemia?

Authors:  Felicitas Thol
Journal:  Haematologica       Date:  2018-03       Impact factor: 9.941

6.  Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.

Authors:  Gunnar Juliusson; Oskar Hagberg; Vladimir Lj Lazarevic; Emma Ölander; Petar Antunovic; Jörg Cammenga; Lovisa Wennström; Lars Möllgård; Mats Brune; Martin Jädersten; Stefan Deneberg; Sören Lehmann; Åsa Rangert Derolf; Martin Höglund
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

Review 7.  Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?

Authors:  Jennifer E Vaughn; Veena Shankaran; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

8.  Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.

Authors:  Karen Sachs; Aaron L Sarver; Klara E Noble-Orcutt; Rebecca S LaRue; Marie Lue Antony; Daniel Chang; Yoonkyu Lee; Connor M Navis; Alexandria L Hillesheim; Ian R Nykaza; Ngoc A Ha; Conner J Hansen; Fatma K Karadag; Rachel J Bergerson; Michael R Verneris; Matthew M Meredith; Matthew L Schomaker; Michael A Linden; Chad L Myers; David A Largaespada; Zohar Sachs
Journal:  Cancer Res       Date:  2019-11-29       Impact factor: 12.701

9.  Efficacy of 10-day decitabine in acute myeloid leukemia.

Authors:  Ian M Bouligny; Vivek Mehta; Scott Isom; Leslie R Ellis; Rupali R Bhave; Dianna S Howard; Susan Lyerly; Megan Manuel; Sarah Dralle; Bayard L Powell; Timothy S Pardee
Journal:  Leuk Res       Date:  2021-02-12       Impact factor: 3.156

Review 10.  Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).

Authors:  Kelly Mitchell; Ulrich Steidl
Journal:  Cold Spring Harb Perspect Med       Date:  2020-01-02       Impact factor: 6.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.